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Objectives: Advanced age is a significant risk factor that has traditionally steered patients away from open aneurysm repair
and toward expectant management. Today, however, the reduced morbidity and mortality of aortic stent grafting has
created a new opportunity for aneurysm repair in patients previously considered too high a risk for open surgery. Here
we report our experience with endovascular aneurysm repair (EVAR) in nonagenarians.
Methods: Retrospective chart review identified all patients >90-years-old undergoing EVAR over a 9-year period at our
institution. Collected data included preoperative comorbidities, perioperative complications, endoleaks, reinterventions,
and long-term survival.
Results: 24 patients underwent EVAR. The mean age was 91.5 years (range 90-94) among 15 (63%) males and 9 (37%)
females. Mean abdominal aortic aneurysm diameter was 6.3  1.1 cm. Eight patients (33%) were symptomatic (pain or
tenderness). There were no ruptures. Fourteen patients (58%) had general anesthesia while 10 (42%) had local or regional
anesthesia. Mean postoperative length of stay was 3.2 2.4 days (2.8  1.9 days for asymptomatic vs 4.1 3.2 days for
symptomatic, P .29). There was one perioperative mortality (4.2%). There were two local groin seromas (8.3%) and six
systemic complications (25%). One patient required reintervention for endoleak (4.2%). There were no aneurysm related
deaths beyond the 30-day postoperative period. Mean survival beyond 30 days was 29.7  18.0 months for patients
expiring during follow-up. Cumulative estimated 12, 24, and 36-month survival rates were 83%, 64%, and 50%,
respectively. Linear regression analysis demonstrated an inverse relationship between the number of preoperative
comorbidities and postoperative survival in our cohort (R2  0.701), with significantly decreased survival noted for
patients presenting with >5 comorbidities. Those still alive in follow-up have a mean survival of 36.1  16.0 months.
Conclusion: This is the largest reported EVAR series in nonagenarians. Despite their advanced age, these patients benefit
from EVAR with low morbidity, low mortality, and mean survival exceeding 2.4 years. Survival appears best in those
patients with<5 comorbidities. With or without symptoms, patients over the age of 90 should be considered for EVAR.
(J Vasc Surg 2010;52:1140-6.)Improvements in medicine have enabled the elderly to
live longer, healthier, more productive lives than ever be-
fore.1 As a result, the elderly are one of the fastest growing
segments of theUS population. By the year 2050, there will
be an estimated 20.9 million Americans over the age of 85,
representing 5% of the entire US population, up from just
1.5% in the year 2000.2 With a current life expectancy of
6.4 years for 85-year-olds, it is projected that many octo-
genarians will live into their 10th decade.3
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1140Cardiovascular disease is one of the most common
causes of morbidity and mortality in this growing elderly
population.3 Treatment of these diseases in elderly pa-
tients with the associated comorbidities is a significant
challenge with attendant risks. The emergence of endo-
vascular procedures has changed the face of vascular
surgery, enabling surgeons to treat elderly patients who
previously could not have endured the stresses and risks
of open surgery. Specifically, endovascular aneurysm re-
pair (EVAR) offers a treatment modality for patients
once thought too frail to undergo traditional open sur-
gical abdominal aneurysmorrhaphy.
While there have been prior analyses of surgical out-
comes in the elderly population, until now these efforts
have focused on octogenarians.4-11 Nonagenarians are typ-
ically incorporated into these larger categories of elderly or
high-risk patients.11,12 We believe that the nonagenarian
population represents a distinct, significant, and growing
segment of the elderly population affected with aortic
aneurysmal disease. In the 10th decade of life, patients will
benefit most from a less invasive approach to repair of a life
threatening entity such as abdominal aortic aneurysm. We
hypothesized that EVAR offers a safe, durable option for
abdominal aortic aneurysm repair in this elderly popula-
tion. Thus, we sought to examine the outcomes of patients
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institution over a 10-year period.
METHODS
We retrospectively reviewed available hospital billing
records at New York Presbyterian Hospital (incorporating
both the Weill Cornell and Columbia Presbyterian cam-
puses) to obtain records of all patients 90 years of age or
older undergoing all vascular surgical procedures over the
period between January 1998 and March 2009. Within
these patients, we discovered a cohort who had underwent
infrarenal abdominal aortic aneurysmorrhaphy between
2001 and 2009. We reviewed hospital charts to collect
patient demographics, intraoperative characteristics, and
postoperative outcomes. Comorbidities for each patient
were analyzed including hypertension, coronary artery dis-
ease (CAD), diabetes mellitus (DM), renal disease (chronic
renal insufficiency and/or end-stage renal disease), smok-
ing history (any current or past regular use of tobacco),
history of myocardial infarction (MI), congestive heart
failure (CHF), chronic obstructive pulmonary disease
(COPD), history of stroke, remote history of transient
ischemic attack (TIA) (this included two patients with
documented events more than 5 years prior to surgery, and
symptoms had resolved with medical therapy), history of
cancer (any current or past incidence of malignancy), hy-
percholesterolemia, previous aortic surgery, previous pe-
ripheral vascular surgery, and peripheral vascular disease.
Physician clinic notes, telephone inquiries, and the Social
Security Death Index were also utilized for postoperative
follow-up.
Surgical technique. Surgeries were performed ac-
cording to generally accepted operating procedures, unless
otherwise noted. Patients were anesthetized with general
(defined as endotracheal tube, or laryngeal mask), or loco-
regional anesthesia (defined as local infiltration plus seda-
tion, or spinal or epidural catheters). Open repairs were
performed via midline laparotomy in all cases, and tube
grafts or bifurcated grafts selected based on anatomy. In
endovascular cases, endografts were deployed using open
femoral artery exposure, fluoroscopic imaging, and iodin-
ated contrast media. Anesthetic choice and endograft selec-
tion were based on patient comorbidities, anatomy, and
surgeon preference. A variety of endovascular grafts were
used including the Zenith Flex/Renu AAA Endovascular
Graft (Cook Medical Inc, Bloomington, Ind), the Talent
Abdominal Stent Graft (Medtronic, Inc, Minneapolis,
Minn), the AneuRx AAAdvantage Stent Graft (Medtronic,
Inc, Minneapolis, Minn), the Gore Excluder AAA Endo-
prosthesis (W. L. Gore & Associates, Inc, Flagstaff, Ariz),
and the Guidant Ancure Endograft System (Guidant Corp,
Indianapolis, Ind).
Outcomes. Outcomes were reported according to the
2002 guidelines set forth by the SVS/AAVS (Society for
Vascular Surgery/American Association for Vascular Sur-
gery).13 Postoperative outcomes included perioperative mor-
tality (defined as deathwithin 30days after surgery), aneurysm
rupture, aneurysm-free survival, endoleak, stroke, and MI.Statistical analysis. Means (standard deviation) and
medians were used to analyze continuous variables. Where
applicable, means were compared using the Student two-
tailed t test and categorical variables were compared using
the Fisher’s exact test. P values of less than 0.05 were
considered to be indicative of statistical significance. Odds
ratios with 95% confidence intervals were calculated to
compare binary event probabilities occurring between
groups. In patients reaching the endpoint of death, linear
regression was used to analyze the correlation between
postoperative survival and preoperative comorbidity. A
Kaplan-Meier curve was constructed, and life table analysis
was used to evaluate cumulative estimated long-term post-
operative survival following endovascular aneurysm repair.
RESULTS
We identified 28 patients undergoing abdominal aortic
aneurysm repair during the study period. Four patients
(two male, two female, mean age 91.3 2.0 years) under-
went open surgical repair: three patients were repaired
emergently for rupture, and one was repaired urgently for a
symptomatic aneurysm that did not meet anatomic criteria
by imaging for endovascular repair. Three of the four open
repairs had imaging performed (one rupture was not im-
aged prior to repair), and the mean abdominal aortic aneu-
rysm (AAA) size was 6.7  0.6 cm. The patients undergo-
ing open repair had an average of 4.5 comorbidities (3, 5, 6,
and 4, for the individual patients). All four patients expired
during the postoperative follow-up. One patient expired on
postoperative day 6 from multisystem organ failure; the
remaining patients survived 3, 8, and 12 months (the
nonruptured, symptomatic patient surviving the longest).
Causes of death following the perioperative period were
respiratory failure, stroke, and myocardial infarction, re-
spectively.
EVAR was successfully performed on the remaining 24
patients, including 15 (63%) males and 9 (37%) females
with an overall mean age of 91.5 1.0 years (range 90-94).
Twenty-two (92%) patients presented with infrarenal aneu-
rysms. One patient underwent endovascular repair of a
hypogastric aneurysm, and one patient underwent repair of
an infrarenal penetrating ulcer. Eight (33%) patients pre-
sented with symptoms of abdominal pain or tenderness. In
the remaining 16 (67%) asymptomatic patients, aneurysms
were diagnosed on routine computed tomography (CT)
scans. Fourteen (58%) patients had general anesthesia, while
10 (42%) had local or regional anesthesia. Twelve Cook
Zenith grafts, 2Medtronic Talent grafts, 9Medtronic Aneurx
grafts, 1 Gore Excluder graft, and 1 Guidant Ancure graft
were used. Grafts were successfully deployed in all patients,
and there were no conversions to open repair.
The mean infrarenal aneurysm diameter was 6.3 
1.1cm for all AAA, and the diameters of the hypogastric
aneurysm and infrarenal ulcer were 4 cm and 3.3 cm,
respectively. Symptomatic AAAs had a mean diameter of
6.4  1.1 cm vs asymptomatic AAAs, which had a mean
diameter of 6.3  1.1 cm (P  .75). All procedures were
elective, with no suspected or confirmed aneurysm ruptures
ated b
ial inf
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performed included 1 iliac angioplasty to allow passage of
the endograft, 3 iliac stent placements within graft limbs, 1
femoral-femoral arterial bypass in a planned aorto-uni-iliac
reconstruction, 1 proximal Palmaz aortic stent, 2 femoral
patch angioplasties, and 1 proximal aortic cuff placement.
Perioperative local complications (groin seroma) oc-
curred in two (8.3%) patients. Perioperative systemic com-
plications occurred in six (25%) patients (patient demo-
graphics, comorbidities, and operative information detailed
in Table I). There was one (4.2%) perioperative death. This
patient suffered a myocardial infarction and expired on
postoperative day 26 following elective EVAR for a 5.3 cm
symptomatic aneurysm and discharge on postoperative day
Table I. Perioperative systemic complications in nonagen
Patient Complication Patient history
4 Myocardial infarction 92F, symptomatic,
general anesthesi
9 Myocardial infarction,
death
91F, symptomatic,
general anesthesi
15 Pulmonary embolism,
gastrointestinal bleed
92F, asymptomatic
general anesthesi
16 Myocardial infarction,
atrial fibrillation
91M, asymptomati
local anesthesia
18 Atrial fibrillation, altered
mental status
91M, asymptomati
general anesthesi
20 Hypotension, troponin
leak
93M, asymptomati
general anesthesi
CAD, Coronary artery disease; CRI, chronic renal insufficiency; EBL, estim
departure from operating room; HTN, hypertension; MI, previous myocard
Table II. Preoperative comorbidities and patient demogra
repair (EVAR)
All patients
(N  24)
Infrarenal AAA size 6.3  1.1 cm
Stent graft proximal neck diameter 28.8  3.8 cm
General anesthesia 14 (58%)
Hypertension 21 (87.5%)
Coronary artery disease 11 (45.8%)
Diabetes 2 (8.3%)
Renal disease 3 (12.5%)
Smoking history 14 (58.3%)
MI history 7 (29.2%)
COPD 4 (16.7%)
Stroke history 3 (12.5%)
Remote transient ischemic attack 2 (8.3%)
Previous vascular surgery 4 (16.7%)
Previous aortic surgery 2 (8.3%)
Cancer 6 (25.0%)
PVD 6 (25.0%)
Cholesterol 8 (33.3%)
CHF 4 (16.7%)
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary
peripheral vascular disease.2. Mean postoperative length of stay was 3.2  2.4 days(2.8  1.9 days for asymptomatic vs 4.1  3.2 days for
symptomatic, P  .29).
Patients presented with a mean of 4.0 ( 2.2) comor-
bidities (Table II). Asymptomatic patients had a larger
mean proximal stent graft neck size than symptomatic
patients (30.3  3.7cm vs 26.2  2.5 cm, P  .006).
Compared with the asymptomatic group, those patients
with symptomatic aneurysms had a significantly higher
incidence of coronary artery disease (87.5% vs 25.0%, P 
.007) and prior myocardial infarction (62.5% vs 12.5%, P
.02). The group of patients receiving general anesthesia had
a higher incidence of coronary artery disease as well (64% vs
20% for those receiving a loco-regional anesthetic, P 
.04). Finally, symptomatic patients were also more likely
s undergoing endovascular aneurysm repair (EVAR)
Comorbidities EBL (cc)
Procedure
length (min)
HTN, CAD, MI, PVD 500 240 (est)
HTN, CAD, smoking,
MI, cancer, cholesterol
200 210 (est)
HTN, smoking 100 161
HTN, smoking, previous
vascular surgery, PVD,
cholesterol
100 300 (est)
HTN, CAD, cancer,
cholesterol, CHF
500 243
HTN, CAD, MI, CRI,
cancer, PVD
200 169
lood loss; est, estimated operative times from records of patient arrival and
arction; PVD, peripheral vascular disease.
s in nonagenarians undergoing endovascular aneurysm
Symptomatic
(N  8)
Asymptomatic
(N  16) P value
6.4  1.1 cm 6.3  1.1 cm .75
26.2  2.5 cm 30.3  3.7 cm .006
7 (87.5%) 7 (44%) .05
8 (100.0%) 13 (81.3%) .52
7 (87.5%) 4 (25.0%) .007
2 (25%) 0 (0.0%) .101
1 (12.5%) 2 (12.5%) 1
4 (50.0%) 10 (62.5%) .67
5 (62.5%) 2 (12.5%) .02
1 (12.5%) 3 (18.8%) 1
1 (12.5%) 2 (12.5%) 1
1 (12.5%) 1 (6.3%) 1
1 (12.5%) 3 (18.8%) 1
0 (0.0%) 2 (12.5%) .53
3 (37.5%) 3 (18.8%) .36
4 (50.0%) 2 (12.5%) .13
3 (37.5%) 5 (31.3%) 1
2 (25.0%) 2 (12.5%) .58
e; CHF, congestive heart failure; MI, previous myocardial infarction; PVD,arian
a
a,
,
a
c,
c,
a
c,
aphic
diseasthan asymptomatic patients to receive a general anesthetic
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systemic complications occurring (Table I), 5 occurred in
patients receiving a general anesthetic (2 symptomatic pa-
tients and 3 asymptomatic patients), and 1 occurred in a
patient receiving local infiltration and intravenous sedation,
(odds ratio [OR] 5.0, 95% confidence interval [CI] 0.5-
51.8).
One type I endoleak (4.2%), and three type II en-
doleaks (12.5%) were identified in three patients during the
postoperative period. One patient had both type I and type
II endoleaks and underwent reinterventions including a
proximal cuff placement and Palmaz aortic stent at 20
months for a type 1 endoleak. She subsequently had unsuc-
cessful coil embolizations performed 9 months later for a
recurrent type 1 endoleak, but was believed too frail to
undergo open conversion. The two remaining patients had
type II endoleaks detected without increase in aneurysm
size and are followed serially.
Among the 23 patients that survived beyond the peri-
operative period, 12 expired during follow-up. There were
no aneurysm related deaths beyond the 30-day postopera-
tive period. The mean and median postoperative survival
among those patients that expired was 29.7 18.0 months
and 25.2 months, respectively. At the time of this report,
the mean and median postoperative survival among the
remaining 11 patients was 36.1  16.0 and 33.6 months
respectively, (range 9.9-59.9 months). Life table analysis
demonstrated cumulative estimated 12, 24, and 36-month
survival rates of 83%, 64%, and 50%, respectively (Table III,
Fig 1).
In the 12 patients who expired during follow-up, linear
regression analysis was performed to examine the correla-
tion between preoperative comorbidity and postoperative
survival (Fig 2). An inverse relationship was demonstrated
between the number of preoperative comorbidities and the
long-term postoperative survival (R2  0.701). Signifi-
cantly decreased survival was noted for patients presenting
with 5 comorbidities (range 3.7-13 months), whereas
patients with five or less comorbidities all survived beyond
Table III. Life table analysis of long-term survival followi
Time
(months)
Number at
risk
Number withdrawing
during interval
N
0 24 0
6 22 1
12 20 0
18 19 1
24 16 2
30 12 3
36 8 1
42 6 1
48 5 1
54 2 0
60 2 120 months (range 22.3-63.0).DISCUSSION
Abdominal aortic aneurysms remain a significant cause
of morbidity and mortality among the general population.
The risk of rupture and its sequelae necessitates repair in
patients with both asymptomatic and symptomatic aneu-
rysms.14 Over the past decade, technological advancements
have resulted in a shift towards EVAR as a safe and effective
alternative to open aneurysm repair. Among the general
population, EVAR has been shown to result in decreased
perioperative mortality compared with open repair, with-
out compromising short-term and mid-term survival.15-17
Bush et al found high-risk patients (which included
patients age 60) to have a significantly decreased 30-day
and 1-year all cause mortality following EVAR vs open
repair.18 Other studies have confirmed EVAR to be safe
and effective in octogenarians, reporting low rates of peri-
operative mortality (0.5%-3.3%) and high rates of technical
success.4,5,9 Yet despite the promising data regarding
EVAR in high-risk and octogenarian patients, the nonage-
narian population specifically has not been widely ad-
dressed in the literature.
Here we report the largest series of nonagenarians
undergoing EVAR. A total of 24 patients, both men and
women, underwent EVAR for symptomatic and asymp-
tomatic AAAs. Operative technical success was 100%, with
one (4.2%) perioperative death. While this perioperative
mortality rate is higher than the 1.2% reported in the
DREAM trial among the general population, it is compa-
rable to rates reported in studies of EVAR in octogenarians,
and lower than the 5.6% to 11% rate reported in the other
published reports on EVAR in nonagenarians.5,9,15,19,20
Moreover, the local and systemic complication rates (8.3%
and 25%, respectively) among our nonagenarian patients is
lower than those reported in octogenarians by Lobato et al
(26% and 18%, respectively), and comparable to those
reported in nonagenarians by Baril et al (22% and 17%,
respectively) and Jim et al (17% systemic complication
rate).8,19,20 The incidence of endoleak in our series was also
in line with published reports: 4.2% incidence of type I
endoleak and 12.5% incidence of type II endoleak in our
dovascular aneurysm repair (EVAR) in nonagenarians
er of terminal
events
Cumulative proportion
surviving at end of interval
Standard
error
2 .92 .06
1 .87 .07
1 .83 .08
2 .74 .09
2 .64 .10
1 .58 .11
1 .50 .12
0 .50 .12
2 .28 .14
0 .28 .14
1 .09 .12ng en
umbseries compared with 6.9% to 10% and 2% to 24.1% (respec-
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of type I endoleak and 11% to 33% incidence of type II
endoleak reported in nonagenarians.8,9,19,20
Baril et al and Jim et al are the only reports to date of
EVAR specifically in nonagenarians. Baril describes an all-
male series exclusively performed with spinal anesthesia
with a perioperative mortality of 11%, and a technical
Fig 1. Kaplan-Meier curve for estimated long-term po
(EVAR) in nonagenarians.
Fig 2. Postoperative survival vs comorbidities in nona
Linear regression of preoperative comorbidities vs post
death, R2  0.701.success rate of 100%, concluding that EVAR was poten-tially beneficial for “suitable” nonagenarian patients.19 Jim
et al references our study, demonstrating a 5.6% perioper-
ative mortality, and includes a slightly more heterogeneous
population.20 Our study expands on the results of both of
these smaller analyses by including the largest sample of
patients, both genders, a comparative experience with both
loco-regional and general anesthesia, a correlation between
rative survival following endovascular aneurysm repair
ians following endovascular aneurysm repair (EVAR).
tive survival (months) in patients reaching endpoint ofstopegenar
operapreoperative comorbidities and long-term survival, and life-
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population. Taken together, these studies strengthen the ar-
gument in favor of treating this elderly, high-risk population,
and guide the clinician as to the best candidates for interven-
tion.
In high-risk patients undergoing EVAR, Timaran et al
reported a higher in-hospital mortality rate among patients
with “the most severe comorbidities” compared with those
with lower comorbidity (1.7% vs 0.4%).21 In our series as
well, among patients that survived beyond the periopera-
tive period, there was a negative correlation (R2  0.701)
between the number of comorbidities and postoperative
survival (Fig 2). Patients with greater than five comorbidi-
ties in our cohort exhibited a sharply decreased long-term
survival, and similar patients in the future may be treated
more conservatively. However, one could be cautioned
against extrapolating this finding to clinical practice as our
study was limited by a small sample size.
Patients with symptomatic aneurysms in our cohort
had a significantly higher incidence of coronary artery dis-
ease and prior myocardial infarction. They were also more
likely than asymptomatic patients to receive a general anes-
thetic. In our study, there was a trend towards systemic
complications (of which five out of six were cardiac in
nature) being associated with general anesthesia (OR 5.0,
95% CI 0.5-51.8). Careful consideration must be given to
the use of general anesthetics in the nonagenarian with a
significant history of coronary artery occlusive disease or
previous myocardial infarction.
As a retrospective study, this report suffers from the
limitation of a sample selection bias, in that the number of
patients over the age of 90 in our treatment area who were
not treated (ie, “the denominator”) is unknown. We un-
successfully attempted to obtain records of those patients
triaged at our hospital in this age group with the diagnosis
of abdominal aneurysm who remained untreated, but were
unable to procure this data. Thus, our cohort may represent
a preselected group healthier and more suitable for EVAR
than the overall group of nonagenarians presenting with
AAA. Additionally, without knowing the outcomes of
those nonagenarians left untreated, it remains unknown if
AAA in the 10th decade may represent a distinct, poten-
tially more indolent natural history that that seen in
younger patients. Having a cohort of nonagenarians with
untreated AAA would allow a comparison of survival be-
tween these groups, and an assessment of the benefit of
intervention, which we were unable to perform. The three
nonagenarian patients who presented to our institution
over the study period with rupture (treated emergently
with open aneurysmorrhaphy), however, reinforce the
deadly potential of this disease even in the 10th decade. The
decreased morbidity of EVAR could have an even more
substantial impact on those nonagenarians presenting with
a ruptured AAA if implemented for this entity.
With the current senescence of the baby boomer gen-
eration, record numbers of Americans are living well into
their 10th decade of life. As such, we believe nonagenarians
to be a growing and distinct population within the UShealthcare system; one whose healthcare needs and con-
cerns must be uniquely addressed. While this study has
demonstrated that EVAR can be safely performed in the
nonagenarian population, there are many unresolved issues
in this group including postoperative surveillance in elderly
patients, the socio-economic constraints of elderly patients
requiring increased medical care and surveillance, and fi-
nally quality of life and cost considerations. Though careful
consideration must be given to each patient individually,
there may also be merit to considering a higher aortic
diameter threshold for intervention in this fragile elderly
population. The symptomatic population treated in our
study had a significantly smaller proximal neck size com-
pared with the asymptomatic group, which may suggest
that the virulence of this entity relates to aneurysm size
relative to the native proximal aorta. These are all topics
requiring further study.
We have presented the largest series to date of endo-
vascular aortic aneurysm repair in nonagenarians with low
morbidity, low mortality, and prolonged aneurysm-free
survival. Clinicians should consider loco-regional anesthet-
ics when suitable, and be cautious in treating elective
patients with greater than five comorbidities. In suitable
patients over 90 years of age, without significant numbers
of comorbidities, EVAR is safe and effective.
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The manuscript by Dr Goldstein and colleagues explores the
issue of repairing abdominal aortic aneurysms in a very special
group of patients, the oldest of old, nonagenarians. They report
their outcomes of endovascular repair (EVAR) in this small and
unique cohort. Given the advanced age of the patients, the authors
show very acceptable morbidity and mortality rates. They do
temper their conclusions with caveats about intervening on pa-
tients with multiple medical comorbidities. It is not unexpected
that the authors found an inverse relationship between the number
of comorbidities and long-term survival. With the largest series to
date in 90 year olds with long-term follow-up, a few distinct
observations should be made.
I believe this article raises the most important concern – the
importance of individual patient selection. The surgeon must
establish a quality patient relationship and exercise excellent pa-
tient and family communication. The nonagenarian and his or her
family must be attuned to the realistic outcomes associated with
this disease process, especially in elderly patients with numerous
comorbidities. We must remind ourselves that in such challenging
situations, just because we can technically perform the procedure,
surgical intervention may not be the right decision for the patient?
This conversation is much easier to approach in the asymptomatic
patient in whom the risk of rupture may be much less than the true
mortality rate of a nonagenarian. National Vital Statistics state that
the general life expectancy for 90-year-olds is 5 years and 3.6 yearssion may be to not intervene, a decision that is generally difficult
for many, both physicians and families alike.
In the Hippocratic Oath, physicians pledge to consider more
than a patient’s pathology but also to realize that “illness may affect
the person’s family and economic stability”. The independent
elderly may end up dependent upon family members or in a skilled
facility following repair, Alternatively, older persons may have a
very fixed and limited income. The expenses associated with EVAR
and themandatory future follow-up imaging (and associated trans-
portation costs) needs to be considered when intervention is being
discussed. Undue stress on a person and/or their family may
represent a worse situation than that of living with the risk of
aneurysm rupture. Due to advances in medical science, nonagenar-
ians, while a small proportion of the population, are increasing in
numbers. These conversations between the patient, families, and
physician will become more commonplace in all medical special-
ties. I fully agree with the authors in their conclusion that perhaps
we must “consider a higher aortic diameter threshold in this fragile
elderly population”. Above all, exercise caution and moderation.
In this special circumstance, posing the question to yourself,
“What would I want done to my parent?” is very appropriate.
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